12:00 PM EST - Immunovaccine Inc. : said it has signed a collaborative agreement with the Dana-Farber Cancer Institute, a principal teaching affiliate of the Harvard Medical School. The research collaboration involves formulating Dana-Farber's HIV protein antigens in Immunovaccine's DepoVax vaccine enhancement and delivery platform. The goal of this preclinical research is to establish whether this novel vaccine formulation will induce a stronger immune response. Immunovaccine Inc.
shares V.IMV are trading up $0.01 at $1.22.
